ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1359	National Cancer Institute	Html	en	Cancer Pain (PDQ®)–Health Professional Version	Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed.	initial pain assessment 0.567168 baseline pain intensity 0.558291 treats mild pain 0.559952 moderate cancer pain 0.617809 metastatic bone pain 0.57198 incident cancer pain 0.559612 acute pain resolves 0.55829 pain management treatment 0.568663 ongoing pain management 0.552517 pain relief ladder 0.55951 common cancer pain 0.591113 Neuropathic Pain sections 0.560808 somatic pain 0.561569 indicates mild pain 0.560721 cancer patients 0.628525 pain intensity 0.56637 pain management 0.652391 neuropathic pain 0.592568 Pain Symptom Manage 0.699092 cancer pain control 0.556765 Pain Management Nursing 0.556277 Pain Physician 0.561182 pain assessment 0.597079 Pain Palliat Care 0.567356 breakthrough cancer pain 0.563775	visceral pain signals 0.562249 severe cancer pain 0.582593 PUBMED Abstract 0.564761 visceral pain 0.565502 pain assessment toolkit 0.554382 mild pain 0.57672 Effective pain management 0.567467 cancer pain management 0.592002 pain relief 0.569023 moderate pain 0.568137 cancer pain 0.834476 American Pain Society 0.557173 pain 0.954306 acute pain 0.572092 Abstract 0.595673 Pain Med 0.572479 Clin Oncol 0.552396 severe pain 0.584777 cancer pain experience 0.579997 pain scale 0.566028 pain levels 0.565618 comprehensive pain assessment 0.576005 indicates moderate pain 0.564768 pain receptors 0.555011	CLICK HERE
1455	National Cancer Institute	Html	en	Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Merkel cell carcinoma.	inadequate surgical margins 0.329956 cell polyomavirus infection. 0.336356 lymph node dissection 0.348903 Australian Merkel cell 0.385562 Distinct merkel cell 0.383584 neuroendocrine) carcinoma. 0.357189 node-positive Merkel cell 0.37626 Cell Carcinoma Information 0.370356 Ann Surg Oncol 0.393202 Rockville Merkel Cell 0.387174 clinical trials 0.331337 distant metastatic disease 0.331199 newly diagnosed patients 0.336848 cell carcinoma tumors 0.386769 Merkel cell cancer 0.385012 metastatic disease 0.334729 advanced merkel cell 0.38315 patients 0.398223 human Merkel cell 0.391488 Merkel cell polyoma 0.396025 lymph node biopsy 0.394484 sentinel lymph node 0.424128 Merkel tumours 0.360064 Merkel cell carcinomas 0.385298 primary Merkel cell 0.398409	et al. 0.396589 wide local excision 0.340871 case series 0.379017 Arch Dermatol 0.332282 cutaneous Merkel-cell carcinoma 0.356835 PUBMED Abstract 0.359039 adjuvant radiation therapy 0.370608 Invest Dermatol 0.331034 neuroendocrine-merkel cell carcinoma 0.369705 MCC patients 0.350161 Surg Oncol 0.397083 merkel cell carcinoma 0.931809 Abstract 0.399239 Clin Oncol 0.38708 cell polyomavirus sequences 0.331565 Dermatol Surg 0.33595 Carcinoma Group 0.350591 cell carcinoma demographics 0.372267 Trabecular carcinoma 0.351339 cell polyomavirus DNA 0.331118 lymph node 0.427173 cell carcinoma adjuvant 0.368757 merkel cell polyomavirus 0.477468 lymph node metastases 0.330714	CLICK HERE
1538	National Cancer Institute	Html	en	Coenzyme Q10 (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of coenzyme Q10 as a treatment for people with cancer.	cell respiration 0.339879 naturally occurring forms 0.338495 new blood cells 0.340323 United States 0.340183 plasma coenzyme 0.469789 clinical examination 0.347068 cell growth 0.340428 animal immune systems 0.339418 cancer cells 0.357416 above-mentioned human studies 0.339569 follow-up study 0.36193 quinone chemical group 0.341067 breast cancer prognosis. 0.348287 cellular energy production 0.369553 cancer therapy 0.341253 free radical damage 0.357523 dietary supplements 0.352656 blood levels 0.35773 IND application process 0.337121 anthracycline anticancer drug 0.341617 cancer information summary 0.355992 coenzyme q10 0.913438 free radicals 0.338619 anthracycline drug doxorubicin 0.340494	high-dose coenzyme 0.460691 uncontrolled clinical study 0.342321 clinical drug research 0.340343 specific disease prevention 0.33723 breast cancer patients 0.409089 adjuvant therapy 0.341472 animal studies 0.378869 Investigational New Drug 0.337296 important cellular components 0.338608 normal blood levels 0.341607 protective effect 0.341278 radiation therapy 0.379802 high-level coenzyme 0.453918 aerobic energy production 0.337109 Low blood levels 0.340721 indirect anticancer activity 0.337514 lung cancer cells 0.348538 single-dose radiation therapy 0.3393 standard therapy 0.337625 coenzyme Q10. 0.469116 benzoquinone compound 0.3465 follow-up study report 0.341395 original study 0.33952	CLICK HERE
1603	National Cancer Institute	Html	en	Essiac/Flor Essence (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Essiac/Flor Essence as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.476893 breast cancer patient 0.447748 peer-reviewed scientific literature 0.505169 Flor Essence 0.910617 Canada’s Emergency 0.483591 Essiac 0.743648 Emergency Drug Release 0.58138 market Essiac 0.538568 Essiac herbal tonics. 0.550519 Flor Essence tea 0.527471 health conditions 0.443693 Drug Release Program 0.5531 cancer information summary 0.4699 IND application 0.450106 clinical drug research 0.445755 Rheum palmatum L. 0.477337 cancer patients 0.491951 Investigational New Drug 0.44454 National Health 0.471032 New Drug Application 0.442963 Canadian Department 0.469814 four-herb recipe 0.472871 preclinical new drug 0.49467 cancer cell line. 0.452401	Health Protection Branch 0.470254 Essiac herbs 0.554006 United States 0.45534 Human/Clinical Studies section 0.535541 specific disease treatment 0.444683 Indian rhubarb root 0.47211 Flor Essence formulas 0.534076 Trifolium pratense L. 0.442662 health tonics 0.472986 Rumex acetosella L. 0.474473 conventional anticancer treatments 0.463312 human breast cancer 0.444889 Cnicus benedictus L. 0.443598 Essence herbal teas. 0.46868 dietary supplements 0.454376 Royal Cancer Commission 0.448762 Essiac’s safety 0.539442 new drug submission 0.492934 cancer patients. 0.445606 breast cancer 0.462902 Human Prescription Drugs 0.462631 Ulmus fulva Michx. 0.475105 cancer 0.532647 Laboratory/Animal/Preclinical Studies section 0.471204	CLICK HERE
1636	National Cancer Institute	Html	en	Cartilage (Bovine and Shark) (PDQ®)–Patient Version	Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.483107 human cancer cells 0.399726 cartilage treatment 0.54785 shark cartilage 0.911115 PDQ cancer information 0.489648 Cancer Complementary 0.397259 lung cancer 0.396037 new blood vessels 0.529873 blood vessel growth 0.688109 clinical trials 0.661965 testing bovine cartilage 0.553086 powdered cartilage products 0.528871 bovine cartilage 0.754583 cancer information summary 0.450971 clinical trial 0.545778 patients 0.414137 randomized clinical trial 0.405563 NCI PDQ cancer 0.409125 cancer information database 0.395004 liquid shark cartilage 0.530016 liquid cartilage products 0.569642 powdered shark cartilage 0.613657 cancer information 0.501779 breast cancer cells 0.394321	shark cartilage products 0.633195 laboratory study 0.408409 cartilage products 0.782377 Complementary Therapies Editorial 0.405419 cancer cells 0.530307 Cancer Information Service 0.450397 preclinical studies 0.47111 cartilage product AE–941/Neovastat 0.510074 dietary supplements 0.394341 National Cancer Institute 0.540172 studies 0.47228 alternative medicine 0.440784 pancreatic cancer cells 0.3965 human cartilage 0.495387 PDQ Cartilage 0.50056 shark cartilage product 0.665863 cartilage 0.96677 animal studies 0.448189 standard cancer treatment 0.405448 alternative therapies 0.399716 cancer information summaries 0.395389 powdered cartilage 0.59313 bovine cartilage product 0.523261 cancer 0.811115	CLICK HERE
1725	National Cancer Institute	Html	en	Inflammatory Breast Cancer	A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm.	breast cancer talk 0.38738 ongoing clinical trials 0.322108 breast cancer biology 0.384329 Cancer Treatment Research 0.336489 MS. Inflammatory breast 0.412908 clinical trials 0.369256 Post-mastectomy radiation therapy 0.322454 breast size 0.368687 peau d'orange 0.322535 primary inflammatory breast 0.413233 adjuvant therapy 0.323679 inflammatory breast cancers 0.456146 neoadjuvant chemotherapy 0.327114 entire affected breast 0.371358 cancer recurrence 0.326653 radiation therapy 0.339981 Adjuvant systemic therapy 0.323571 Cancer Survival 0.32586 Cancer Journal 0.32501 invasive breast cancers 0.36818 women 0.331101 sponsors clinical trials 0.32312 Breast reconstruction 0.363182 multimodal approach 0.325682 cancer cells 0.367244	Breast Diseases 0.36337 M. Inflammatory breast 0.415692 HER2-positive breast cancer 0.393048 National Cancer Database 0.332281 nci-supported clinical trials 0.33341 National Cancer Institute 0.374989 hormone therapy 0.325328 estrogen-dependent cancer cells 0.336098 breast carcinoma incidence 0.386211 African American women 0.324285 Inflammatory breast tumors 0.439717 lymph vessels 0.32463 cancer detection 0.328538 neoadjuvant HER2-directed therapy 0.322104 inflammatory breast carcinoma 0.435431 dense breast tissue 0.375347 abnormal breast warmth 0.375148 inflammatory breast cancer 0.961199 Swollen lymph nodes 0.324354 cancer clinical trials 0.346503 Clinical Cancer Research 0.336483 postoperative radiation therapy 0.322326 et al 0.375354 cancer patient 0.327473	CLICK HERE
2067	National Cancer Institute	Html	es	Terapia hormonal para el cáncer de seno	Hoja informativa que describe la terapia hormonal y su función en la prevención y tratamiento del cáncer de seno. Incluye información acerca de los efectos secundarios posibles y de los fármacos que pueden interferir con la terapia hormonal.	Surgical Adjuvant Breast 0.34336 Lancet Oncology 0.360626 Sestak I 0.320955 seno her2 y HR 0.354769 endocrine-responsive early breast 0.32332 endocrine therapy 0.324855 Preventing breast 0.319374 advanced breast 0.370204 Adjuvant hormonal therapy 0.333366 Cuzick J 0.320795 Vogel VG 0.310952 as adjuvant treatment 0.327521 efectos agonistas 0.311137 combined survival analysis 0.309596 Pippen J 0.31114 randomized trial comparing 0.312309 Collaborative Group 0.311107 seno hr 0.420398 hormonal therapy 0.348519 PubMed Abstract 0.906244 Surgical Oncology Clinics 0.312057 Clinical Oncology 0.330375 with advanced breast 0.322297 prior endocrine therapy 0.310537 early breast cancer 0.522236	alto riesgo 0.314676 hormonas estrógeno 0.407972 Bowel Project 0.309666 Wickerham DL 0.323539 aromatasa anastrozol 0.350666 initial adjuvant therapy 0.311523 Breast Cancer Group 0.336508 Costantino JP 0.33801 P-2 Trial 0.309919 Bowel Project Study 0.309651 seno er 0.390638 developing invasive breast 0.321634 standard hormonal therapy 0.329685 adjuvant endocrine therapy 0.312843 Italian Tamoxifen Anastrozole 0.312927 breast cancer 0.858969 Breast Cancer Trialists 0.369705 IBIS-I breast 0.319452 Forbes JF 0.31136 enzima llamada 0.312883 tamoxifen treatment 0.320843 Cancer Institute 0.344896 seno her2 0.38128 primary breast 0.320324	CLICK HERE
3421	National Cancer Institute	Html	es	Antioxidantes y prevención del cáncer	Antioxidants are substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. Antioxidants interact with and stabilize free radicals and may prevent some of the damage fre	nutrition intervention trial 0.318966 Population Nutrition Intervention 0.307215 Minerales Antioxidantes 0.329026 mortality during 0.312847 skin cancers 0.309111 Hercberg S 0.31386 complementos antioxidantes alimenticios 0.358441 vitamina c 0.306663 vitamina a 0.307237 Klein EA 0.307093 vitamina e 0.306864 Virtamo J 0.307865 mortality after 0.306705 antioxidantes alimenticios 0.533634 stopping antioxidant vitamins 0.315828 Internal Medicine 0.308526 Estados Unidos 0.333664 antioxidant vitamins 0.315879 PubMed Abstract 0.94039 Estudio Demográfico 0.30775 follow-up after stopping 0.328778 after stopping antioxidant 0.315902 skin cancers during 0.306731 minerales selenio 0.30885 health beneficial effects 0.308495	randomized controlled 0.317735 International Journal 0.310662 health effects 0.306579 Kristal AR 0.308705 tomar complementos 0.660547 Taylor PR 0.316391 Ezzedine K 0.307269 general population 0.307041 supplemental alpha-tocopherol 0.309241 Kesse-Guyot E 0.307458 tract cancers 0.32431 médicos varones 0.307704 beta carotene 0.315537 elemento mineral selenio 0.311109 Cancer Prevention Study 0.31922 Cancer Prevention Trial 0.339926 complementos alimenticios 0.353561 retinol efficacy trial 0.343648 SU.VI.MAX Study 0.30914 radicales libres 0.808852 resultados mixtos 0.310828 Cancer Institute 0.352968 New England Journal 0.317494 Cancer Prevention 0.362527	CLICK HERE
15584	National Cancer Institute	Html	en	Childhood Cancer Genomics (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.	childhood cancers 0.451916 genomic landscape 0.448565 leukemia cell lines 0.468388 Leukemia Group study 0.460885 Pediatric Acute Myeloid 0.449186 B-cell precursor 0.478228 childhood B-cell precursor 0.465086 B-acute lymphoblastic leukemia 0.506359 poor prognosis 0.440387 mutations 0.5002 children 0.490055 acute lymphoblastic leukaemia 0.700198 specific mutations 0.439289 AML 0.440256 Childhood Acute Lymphoblastic 0.50969 acute lymphoblastic leukemias 0.496998 chromosomal abnormalities 0.446518 CEBPA mutations 0.439533 oncology group study 0.489092 leukemia development 0.4551 B-precursor Acute Lymphoblastic 0.495043 patients 0.462491 prognostic significance 0.476271 Nat Genet 0.458917 Hyperdiploid leukemia cells 0.465322	childhood cancer 0.441528 et al. 0.603959 lymphoblastic leukemia interacts 0.498545 high-risk acute 0.4447 pre-B cell leukemia 0.456422 Pediatr Blood Cancer 0.444419 acute myeloid leukemia 0.542492 Moorman AV 0.468863 acute lymphocytic leukemia 0.496126 acute lymphoblastic leukaemias 0.511116 favorable prognosis 0.439188 point mutations 0.44293 B-acute lymphoblastic leukaemia 0.466866 cases 0.445244 genomic alterations 0.438134 Abstract 0.573806 Clin Oncol 0.509945 favorable outcome 0.455497 blood 0.45817 Acute promyelocytic leukemia 0.495963 pathogenic germline mutations 0.450974 acute lymphoblastic leukemia 0.983229 acute leukemia 0.50127 Mullighan CG 0.471025	CLICK HERE
16834	National Cancer Institute	Html	en	Benefits of Nanotechnology for Cancer	Nanotechnology offers specific benefits that will enable the future of cancer care. Find out here what these benefits are.	red blood cells 0.289952 cancer treatment 0.2825 tumor endothelium barriers 0.421993 tumor blood vessels 0.384277 tumor interstitial fluid 0.381214 leaky vasculature 0.26567 drug delivery 0.676613 relatively large nanoparticles 0.291836 tumor region 0.406678 higher intratumoral accumulation 0.251171 traditional biological barriers 0.261085 nanoparticles 0.370499 negatively charged nanoparticles 0.284913 solid tumor treatment 0.521666 tumor site 0.484864 tumor stroma 0.468242 cancer drug delivery 0.312793 larger tumor mass 0.494058 acidic environment 0.280266 passive tumor accumulation 0.557879 e.g. biological barriers 0.246569 pancreatic cancer therapy 0.239135 tumor endothelium barrier 0.389992 large biological molecules 0.246874 cancer treatment efficacy 0.244109	tumor mass 0.83917 tumor tissue 0.353798 tumor stroma barrier 0.402359 fast growing tumor 0.412482 cancer cells 0.319257 acceptable drug delivery 0.271477 pancreatic cancer 0.267558 generation nanoparticle therapeutics 0.242211 nanoscale devices 0.277755 tumor cells 0.444134 e.g. functional barriers 0.237198 tumor masses 0.357375 Pancreatic cancer stroma 0.2599 interstitial fluid pressure 0.415697 water-insoluble nanoparticles 0.237625 biological barriers 0.281667 nanoparticle ‘passive tumor 0.434599 tumor penetration 0.354635 nanoparticle surface modification 0.243794 pancreatic cancer cell 0.255371 poorly functioning vasculature 0.239508 EPR effect 0.941886 efficient passive tumor 0.412347 tumor microenvironment 0.390631	CLICK HERE